share_log

RBC Capital Downgrades Sangamo Therapeutics to Sector Perform, Lowers Price Target to $2

RBC Capital Downgrades Sangamo Therapeutics to Sector Perform, Lowers Price Target to $2

加拿大皇家银行资本将Sangamo Therapeutics的评级下调至行业表现,将目标股价下调至2美元
Benzinga ·  2023/11/03 06:20

RBC Capital analyst Luca Issi downgrades Sangamo Therapeutics (NASDAQ:SGMO) from Outperform to Sector Perform and lowers the price target from $6 to $2.

加拿大皇家银行资本分析师卢卡·伊西将Sangamo Therapeutics(纳斯达克股票代码:SGMO)的评级从跑赢大盘下调至行业表现,并将目标股价从6美元下调至2美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发